DK1501921T3 - Forbedrede virusrensningsmetoder - Google Patents

Forbedrede virusrensningsmetoder

Info

Publication number
DK1501921T3
DK1501921T3 DK03724692T DK03724692T DK1501921T3 DK 1501921 T3 DK1501921 T3 DK 1501921T3 DK 03724692 T DK03724692 T DK 03724692T DK 03724692 T DK03724692 T DK 03724692T DK 1501921 T3 DK1501921 T3 DK 1501921T3
Authority
DK
Denmark
Prior art keywords
improved virus
cleansing methods
virus cleansing
methods
improved
Prior art date
Application number
DK03724692T
Other languages
English (en)
Other versions
DK1501921T4 (da
Inventor
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29406789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1501921(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of DK1501921T3 publication Critical patent/DK1501921T3/da
Application granted granted Critical
Publication of DK1501921T4 publication Critical patent/DK1501921T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK03724692.3T 2002-04-30 2003-04-28 Forbedrede virusrensningsmetoder DK1501921T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37727302P 2002-04-30 2002-04-30
US44317603P 2003-01-29 2003-01-29
PCT/CA2003/000624 WO2003093463A1 (en) 2002-04-30 2003-04-28 Improved viral purification methods

Publications (2)

Publication Number Publication Date
DK1501921T3 true DK1501921T3 (da) 2009-06-22
DK1501921T4 DK1501921T4 (da) 2012-10-08

Family

ID=29406789

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03724692.3T DK1501921T4 (da) 2002-04-30 2003-04-28 Forbedrede virusrensningsmetoder

Country Status (16)

Country Link
US (3) US7223585B2 (da)
EP (1) EP1501921B2 (da)
JP (1) JP2005523722A (da)
AR (1) AR039783A1 (da)
AT (1) ATE427990T1 (da)
AU (1) AU2003229159B2 (da)
BR (1) BR0309659A (da)
CA (1) CA2482512C (da)
DE (1) DE60327069D1 (da)
DK (1) DK1501921T4 (da)
ES (1) ES2323454T5 (da)
IL (1) IL164551A (da)
MX (1) MXPA04010603A (da)
NZ (1) NZ535944A (da)
TW (1) TWI317378B (da)
WO (1) WO2003093463A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523722A (ja) 2002-04-30 2005-08-11 オンコリティクス バイオテック， インコーポレイティッド 改善されたウイルス精製方法
ATE478137T1 (de) 2003-06-20 2010-09-15 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
US8373381B2 (en) 2005-04-22 2013-02-12 GM Global Technology Operations LLC DC/DC-less coupling of matched batteries to fuel cells
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
ATE539149T1 (de) 2006-04-20 2012-01-15 Wyeth Llc Reinigungsverfahren zur isolierung von gereinigtem vesikulärem stomatitisvirus aus zellkultur
US20080131955A1 (en) * 2006-11-30 2008-06-05 Canon U.S. Life Sciences, Inc. Method of Separating Target DNA from Mixed DNA
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
KR20110074563A (ko) * 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
MX337348B (es) * 2011-04-29 2016-02-29 Oncolytics Biotech Inc Metodos para purificar virus utilizando cromatografia de permeacion en gel.
MX364690B (es) * 2013-03-15 2019-05-06 Childrens Hospital Philadelphia Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero.
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
WO2015106951A1 (en) * 2014-01-14 2015-07-23 Koninklijke Philips N.V. Organic light emitting diode
WO2016130569A1 (en) * 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
EP3793686A1 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
CA3103963A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
JP2021530548A (ja) 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 遺伝子治療製剤を生産するための系および方法
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
MX2021008542A (es) 2019-01-18 2021-11-12 Voyager Therapeutics Inc Métodos y sistemas para la producción de partículas de aav.
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2021041485A1 (en) 2019-08-26 2021-03-04 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4301768A2 (en) 2021-03-03 2024-01-10 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20220298547A1 (en) * 2021-03-19 2022-09-22 Pathogendx, Inc. Multiplex Viral Pathogen Analysis and Uses Thereof
US20260085328A1 (en) 2022-09-08 2026-03-26 Voyager Therapeutics, Inc. Controlled expression of viral proteins
AU2024256288A1 (en) * 2023-04-21 2025-08-07 National Research Council Of Canada Improvement in viral extraction from cell culture

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721675A (en) 1982-02-01 1988-01-26 Abbott Laboratories Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system
JPS6344532A (ja) 1986-08-11 1988-02-25 Biseibutsu Kagaku Kenkyusho:Kk 豚のレオウイルス感染症ワクチン
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2696748B1 (fr) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
US5614413A (en) 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US6686200B1 (en) 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
ATE328068T1 (de) 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
AU722196B2 (en) * 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
ATE353956T1 (de) 1996-12-13 2007-03-15 Schering Corp Methoden zur virus-reinigung
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6214333B1 (en) 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
AU2001275191A1 (en) 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
DK2253701T3 (da) 2001-03-16 2014-10-20 Oncolytics Biotech Inc Fremgangsmåde til ekstraktion af en virus fra en cellekultur
JP2005523722A (ja) * 2002-04-30 2005-08-11 オンコリティクス バイオテック， インコーポレイティッド 改善されたウイルス精製方法
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods

Also Published As

Publication number Publication date
US10167452B2 (en) 2019-01-01
EP1501921B1 (en) 2009-04-08
US20070269856A1 (en) 2007-11-22
IL164551A (en) 2010-05-17
AR039783A1 (es) 2005-03-02
CA2482512A1 (en) 2003-11-13
JP2005523722A (ja) 2005-08-11
ES2323454T3 (es) 2009-07-16
TWI317378B (en) 2009-11-21
US20040005693A1 (en) 2004-01-08
TW200401829A (en) 2004-02-01
US7223585B2 (en) 2007-05-29
AU2003229159A1 (en) 2003-11-17
US20140178969A1 (en) 2014-06-26
MXPA04010603A (es) 2004-12-13
WO2003093463A1 (en) 2003-11-13
NZ535944A (en) 2007-11-30
BR0309659A (pt) 2005-02-22
CA2482512C (en) 2011-09-20
EP1501921A1 (en) 2005-02-02
ATE427990T1 (de) 2009-04-15
HK1070670A1 (en) 2005-06-24
DK1501921T4 (da) 2012-10-08
US8685734B2 (en) 2014-04-01
EP1501921B2 (en) 2012-07-25
DE60327069D1 (de) 2009-05-20
ES2323454T5 (es) 2012-11-14
IL164551A0 (en) 2005-12-18
AU2003229159B2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
DK1501921T4 (da) Forbedrede virusrensningsmetoder
NO20054134D0 (no) Renseprosess
DE60319273D1 (de) Entzunderungsdüse
IS8476A (is) Lifrarbólgu C-veirutálmar
IS8475A (is) Lifrarbólgu C-veirutálmar
DE60231200D1 (de) Geschirrspülmaschine
IS7405A (is) thynnupakkningatæki
DE60318132D1 (de) Haarwaschmittel
DK1571942T3 (da) Tandbörste
DE60329874D1 (de) Haarwaschmittel
DE60319547D1 (de) Haarwaschmittel
IS7831A (is) Bóluefni
EP1692279A4 (en) VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
DE50200855D1 (de) Geschirrspülmaschine
DE60232038D1 (de) Sicherheitsgurtpresentiereinrichtung
DE60315668D1 (de) Waschmittelteilchen
DE60328408D1 (de) Impfstoff
EP1585433A4 (en) DETECTION METHODS
FI20021957L (fi) Lipeäruisku
DE60335978D1 (de) Haarwaschmittel
EP1544324A4 (en) ablation solution
NO20051561D0 (no) Vaksine
DE60309627D1 (de) Haarbürste
NO20032637D0 (no) Tannbörste
DE602004024640D1 (de) Reinigung von titantetrachlorid